# Montelukast for Prevention & Treatment of OHSS

> **NCT03794037** · PHASE2 · SUSPENDED · sponsor: **Benha University** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Hyperstimulation Syndrome

## Interventions

- **DRUG:** dydrgesterone 10 mg( tab)/12hs/14 days
- **COMBINATION_PRODUCT:** montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days

## Key facts

- **NCT ID:** NCT03794037
- **Lead sponsor:** Benha University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-12-05
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** no fund
- **Last updated:** 2022-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794037, "Montelukast for Prevention & Treatment of OHSS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03794037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*